Budget 2016: Experts sceptical of budget booster to Jan Aushadhi

NEW DELHI: Students from a clutch of Indian colleges have come up with two innovations in the communications space. Presented at the recently held 'Tata IIT Delhi Pioneer's Makerthon', a competition to build the messaging tool of the future. The competition was jointly created by 'Tryst', a technical event of IIT Delhi and the Tata group 

The winning team 'Pojo' comprised of Ankur Singh, Indraprastha Institute of Information Technology (IIIT Delhi), Ishan Khanna, Bhagwan Parshuram Insti .. 

Read more at:
http://economictimes.indiatimes.com/articleshow/51210317.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Engineering students come up with low bandwidth video conferencing tool and messaging app

NEW DELHI: Students from a clutch of Indian colleges have come up with two innovations in the communications space. Presented at the recently held 'Tata IIT Delhi Pioneer's Makerthon', a competition to build the messaging tool of the future. The competition was jointly created by 'Tryst', a technical event of IIT Delhi and the Tata group 

The winning team 'Pojo' comprised of Ankur Singh, Indraprastha Institute of Information Technology (IIIT Delhi), Ishan Khanna, Bhagwan Parshuram Insti .. 

Read more at:
http://economictimes.indiatimes.com/articleshow/51210317.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

The art of drawing: Sir Peter Cook completes first ever building in the UK

ARCHITECTURE / 3 MAR 2016 / BY ELLIE STATHAKI

Sir Peter Cook and his office CRAB (Cook Robotham Architectural Bureau) have just completed the drawing studio at the Arts University Bournemouth - the first of its kind to be built in the UK in 100 years

___________________________________________

Celebrating the art of drawing – and teaching – the Arts University Bournemouth has just launched its brand new drawing studio, the first of its kind to be built in the UK in 100 years. 

The striking blue structure features the playful, organic-shaped volumes that form the signature of its creator; AUB alumnus and renowned architect and academic Sir Peter Cook and his office CRAB (Cook Robotham Architectural Bureau). 

The structure, purpose-built for the art school, will be accessible to students from all courses across the University. Its clean white and generous interior is flexible enough to be able to accommodate work by several different disciplines - from costume design, to architecture, animation and etching. 

Special attention was given to the room's openings and the direction of natural sunlight. A large north-facing opening on the roof brings in the type of light that is traditionally optimum for drawing. At the same time, a rear clerestory window tops up with softer light from the back. 

'As an alumnus of AUB, I am deeply honoured that this University, where I learnt my craft, is now home to my first building in the UK,' says Cook. 'The studio represents a fundamental recognition of the importance of drawing for all creative subjects. When it came to the design of the studio I wanted to ensure I created a space which all students, from all disciplines – be it fashion design, graphic design, fine art, or architecture like me – could make use of and feel inspired in.'

Highlighting the project's importance, Dame Zaha Hadid is set to attend the official opening today. This inauguration also marks Sir Peter Cook's very first built work in the UK.

Read more at http://www.wallpaper.com/architecture/the-art-of-drawing-sir-peter-cook-completes-first-even-building-in-the-uk#Sd6CFvrbMGCJGR77.99

Sun Pharma looking to leverage Ranbaxy OTC drugs: Dilip Shanghvi

India’s largest drugmaker Sun Pharmaceutical is looking to leverage the over-the-counter (OTC)  drugs’ portfolio of Ranbaxy Laboratories, which it acquired two year, to expand its global presence.

Sun Pharma had no presence in the high-volumes OTC segment — medicines sold directly to a consumer without prescription — before the acquisition of Ranbaxy. It recently rolled out its first OTC  drug, antacid Pepmelt, that will compete with Eno, Digene and Pudin Hara.

“Our consumer healthcare, or OTC business is a result of acquisition of Ranbaxy. It is a high-margin, high-growth business. We want to use this as a base to create a global OTC business,” Dilip Shanghvi, managing director, Sun Pharma told HT. “So, we are actually giving lot of internal focus and importance to it.”

When Sun Pharma acquired Ranbaxy, consumer healthcare was the latter’s fastest-growing businesses, with leading brands such as Revital, Volini, Chericof, Pepfiz and Garlic Pearls. Ranbaxy has 15 OTC products, which contributed over 20% of Ranbaxy’s sales before acquisition.

“The two top-growing segments in OTC are health supplements and analgesics and we are witnessing growth healthier than growth rate of the entire OTC market,” said Subodh Marwah, vice-president — consumer healthcare business, Sun Pharma. “So we are actually giving lot of internal focus and importance on growing that part of the business.”

“Consumer health business is important for our future growth not only in India but in other markets where we have presence, where our idea is to grow the business and look at potential inorganic opportunities,” Shanghvi said.

According to market analysts, OTC medicines contribute 10% to 15% to Sun Pharma’s revenues. Brands such Revital (health supplement) and Volini (analgesic) feature among top 10 brands of the country and Sun Pharma is likely to make significant investment in these categories.

As per Neilsen estimates, the antacids category is currently pegged at over Rs 1,180 crore, growing at around 21% every year. The total OTC market in India is pegged at around Rs 5,300 crore, growing annually at around 12% to 13%.

SOURCE: Himani Chandna, Hindustan Times, New Delhi  |  Updated: Mar 03, 2016 17:48 IST

Eli Lilly launches once-a-week diabetes drug in India

"India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India," Olaizola said. 

In a move to enhance its diabetes portfolio in India, US pharma major Eli Lilly has launched once-a-week diabetes treatment drug under the brand name 'Trulicity', at Rs 2,499 in the country. The company has launched the product after receiving the regulatory approval for the same in India. "We are pleased to be introducing Trulicity, first, once-a-week diabetes medicine, in India. We have been committed to diabetes for more than 90 years. We are bringing a new medication to India with a proven efficacy," Eli Lilly India Managing Director Edgard Olaizola told PTI. "The medicine is an injectable medication and belongs to a class called GLP-1 receptor agonists. It is not a insulin," he added. Trulicity comes in a single-dose pen and is designed to improve the blood sugar control in adults with Type 2 diabetes. "India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India," Olaizola said. For Eli Lilly, diabetes is the biggest segment with "about 85 percent of our sales in India coming from diabetes and we are growing double digit and growing our market share," he added. After diabetes, the other important segment is oncology. The others are osteoporosis and human growth hormone, he added. The company is also looking to introduce another medication in oncology. "We are working to bring an oncology product to India and we are working with regulatory agencies for this," Olaizola said. The company expects to introduce the product by next year, he added. Eli Lilly sells a range of medicines and drug delivery devices in the diabetes segment. In 2014, it had introduced Savvio, an insulin delivery device in India.

Read more at: http://www.moneycontrol.com/news/business/eli-lilly-launches-once-a-week-diabetes-drugindia_5744581.html?utm_source=ref_article